Ascentage Pharma Announces Nine Abstracts To Be Presented at the 2019 American Association for Cancer Research Annual Meeting

ROCKVILLE, Md. and HONG KONG, March 25, 2019 /PRNewswire/ -- Ascentage Pharma, globally-focused, clinical-stage biopharmaceutical company developing novel small molecule therapies for cancers, hepatitis B and age-related diseases, today announced that research results of its pipeline of small molecule therapeutics will be presented at the 2019 American Association for Cancer Research (AACR) annual meeting in Atlanta, March 29-April 3, 2019.

AACR abstracts include:

• Title: Predicting Drug Sensitivity to A Novel BCL-2 and BCL-xL Dual Inhibitor In Solid Tumor PDX Trials
  Session Title: BCL-2 Family Proteins
  Session Date and Time: Monday, April 1, 2019 1:00 PM - 5:00 PM EDT
  Poster Number: 2503
• Title: MDM2 Inhibitor APG-115 Synergizes With CDK4/6 Inhibitors In A Patient Derived Xenograft Model of Dedifferentiated Liposarcoma
  Session Title: Credentialing of Molecular Targets
  Session Date and Time: Monday, April 1, 2019 8:00 AM – 12:00 PM EDT
  Poster Number: 1253
• Title: Activation of P53 In the Tumor Microenvironment by MDM2 Inhibitor APG-115 Synergizes With PD-1 Blockade Independently of P53 Status of Tumor Cells
  Session Title: Combination Immunotherapies 2
  Session Date and Time: Tuesday, April 2, 2019 8:00 AM - 12:00 PM EDT
  Poster Number: 3192
• Title: BCL-2 Selective Inhibitor APG-2575 Synergizes with BTK Inhibitor in Preclinical Xenograft Models of Follicular Lymphoma and diffuse Large B-cell Lymphoma
  Session Title: Apoptosis, Necrosis, and Cancer Cell Survival
  Session Date and Time: Monday, April 1, 2019 1:00 PM – 5:00 PM EDT
  Poster Number: 2058
• Title: Synergistic Effect of BCL-2 Inhibitor APG-2575 and CDK9 Inhibitor in Acute Myeloid Leukemia and DLBCL Preclinical Tumor Models
  Session Title: Novel Antitumor Agents 1
  Session Date and Time: Tuesday, April 2, 2019 8:00 AM – 12:00 PM EDT
  Poster Number: 3068
• Title: FAK Blockade Enhances Antitumor Effect of BTK Inhibitor In Esophageal Squamous Cell Carcinoma via EGFR-ERK-Akt Pathway Inhibition
  Session Title: Combination Approaches to Novel Therapies
  Session Date and Time: Sunday, March 31, 2019 1:00 PM – 5:00 PM EDT
  Poster Number: 309
• Title: A Novel Bcl-2/Bcl-XL Inhibitor APG-1252-12A as A Potential Therapeutic Strategy for Gastric Carcinoma
  Session Title: Apoptosis, Necrosis, and Cancer Cell Survival
  Session Date and Time: Monday, April 1, 2019 1:00 PM – 5:00 PM EDT
  Poster Number:2054
• Title: FAK Inhibition Reduces Tumor Infiltration of Tregs Via Restricting CCL5 Release and Boosts the Present Therapeutic Regimen for BRAF^V600E -mutated Colorectal Carcinoma
  Session Title: Immunomodulation by Chemotherapy and Targeted Agents
  Session Date and Time: Tuesday, April 2, 2019 1:00 PM – 5:00 PM EDT
  Poster Number: 3958
• Title: Novel FAK/ALK/ROS1 Inhibitor APG-2449 Synergizes with Osimertinib in Preclinical Xenograft Models of EGFR-mutant NSCLC
  Session Title: Tyrosine Kinase and Phosphatase Inhibitors 2
  Session Date and Time: Monday, April 1 2019 1:00 PM – 5:00 PM EDT
  Poster Number: 2204

About Ascentage Pharma
Ascentage Pharma is a globally-focused, clinical-stage biopharmaceutical company developing novel small molecule therapies for cancers, hepatitis B and age-related diseases. The Company's expertise is in developing therapeutics that inhibit protein-protein interactions to restore apoptosis, or programmed cell death. Ascentage has built a rich pipeline of eight clinical candidates, including a novel, highly potent Bcl-2/Bcl-xL inhibitor, APG-1252, as well as candidates aimed at IAP and MDM2-p53 pathways, and next-generation tyrosine kinase inhibitors. For more information, please visit www.ascentagepharma.com.

Media Contact

Hill+Knowlton Strategies (Hong Kong)
Joanne Lam / Morning Zhu
Tel: +852 2894 6211 / 2894 6227
Email: [email protected] / [email protected]

SOURCE Ascentage Pharma

Related Links

www.ascentagepharma.com